Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 23.32M P/E - EPS this Y - Ern Qtrly Grth -
Income -3.09M Forward P/E - EPS next Y - 50D Avg Chg 4.00%
Sales 163.53k PEG - EPS past 5Y - 200D Avg Chg 32.00%
Dividend N/A Price/Book N/A EPS next 5Y - 52W High Chg -23.00%
Recommedations - Quick Ratio 0.35 Shares Outstanding 89.77M 52W Low Chg 150.00%
Insider Own 15.27% ROA -134.33% Shares Float 76.41M Beta -0.45
Inst Own 0.01% ROE - Shares Shorted/Prior -/- Price 0.33
Gross Margin - Profit Margin - Avg. Volume 5,937 Target Price -
Oper. Margin -1,575.55% Earnings Date Nov 26 Volume 3,000 Change -4.55%
About DIAGNOS INC

DIAGNOS Inc. provides software-based services for healthcare sector in Canada, the United States, Mexico, Chile, and internationally. The company offers healthcare services through Computer Assisted Retina Analysis, a web-based software tool that assists healthcare professionals for the detection of diabetic retinopathy; and allows eye care specialist to visualize both normal retinal landmarks and pathological changes. It also provides various consulting services in the fields of data analysis and artificial intelligence. DIAGNOS Inc. was founded in 1998 and is headquartered in Brossard, Canada.

DIAGNOS INC News
11/12/24 DIAGNOS Announces Cross-listing of its Common Shares on the Frankfurt Stock Exchange
10/25/24 DIAGNOS Announces Closing of Private Placement
10/17/24 DIAGNOS Announces the Engagement of Market Maker Consultant
10/03/24 DIAGNOS Announces Grant of Stock Options
09/26/24 DIAGNOS Announces Voting Results of Meeting of Shareholders
09/23/24 DIAGNOS Announces Variation in One Insider Ownership
08/23/24 DIAGNOS First Quarter 2025 Earnings: EPS Beats Expectations, Revenues Lag
08/22/24 DIAGNOS Announces Date of Annual General and Special Meeting of Shareholders
08/20/24 DIAGNOS Successfully Completes ISO 13485 / MDSAP Audit and receives its certification to move forward with FDA and Health Canada
06/05/24 DIAGNOS Announces Closing of Second and Final Tranche of Private Placement
05/21/24 DIAGNOS celebrates the launch of Labtician’s new screening service for diabetic retinopathy in Ontario and renews its distribution agreement
05/09/24 DIAGNOS Announces Closing of First Tranche of Private Placement
05/06/24 DIAGNOS to Present Cutting-Edge AI Solutions for Retinal Health at ARVO 2024
04/16/24 DIAGNOS to expedite application for Medical Device License to Health Canada and US FDA related to its 4 new analysis modules, and is planning ISO 27001 certification
04/12/24 AI & Technology Hybrid Investor Conference Agenda: Presentations Now Available for Online Viewing
04/09/24 AI & Technology Hybrid Investor Conference Presented by Water Tower Research Agenda Announced for April 10 and 11
04/09/24 DIAGNOS Inc. to Present at the AI & Technology Hybrid Investor Conference April 11th
04/02/24 DIAGNOS Welcomes Dr. Philippe Couillard to its Board of Directors
03/01/24 DIAGNOS Third Quarter 2024 Earnings: Revenues Beat Expectations, EPS In Line
02/29/24 DIAGNOS Welcomes Mr. Michael Braeuel to its Board of Directors